par Longeval, E.;Gangji, Diamon 
;Stryckmans, Pierre ;Kenis, Yvon
Référence CANCER CHEMOTHER.REP., 59, 6, page (1173-1175)
Publication Publié, 1975
;Stryckmans, Pierre ;Kenis, Yvon Référence CANCER CHEMOTHER.REP., 59, 6, page (1173-1175)
Publication Publié, 1975
Article révisé par les pairs
| Résumé : | Phase I-II trial of mitoclomine in chronic lymphocytic leukemia (CLL) is described. Twenty seven courses of mitoclomine were given to 20 patients. This phase I-II study shows that mitoclomine is an active agent in reducing both blood lymphocytosis and organ infiltration in CLL. The neutropenic effect seems to be less important than the lymphopenic effect. Nevertheless, severe neutropenia which was observed in half of the patients represents the greatest threat in the administration of mitoclomine. Gastrointestinal side effects are tolerable in most patients and no alopecia is noted. When mitoclomine is given as a continuous treatment the daily dose of 100 mg seems sufficient to obtain a good therapeutic response. It should be worthwhile to test an intermittent dosage schedule, which was proven useful with chlorambucil. We propose to compare mitoclomine with other agents active in CLL in terms of therapeutic effectiveness and cross resistance. |
